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INTRODUCTION
Sepsis caused by infection remains a major cause of mortal-
ity and morbidity among children in Latvia and throughout
the world (Proulx et al., 1996; Watson et al., 2005). Hospi-
tal mortality among USA children with severe sepsis was
10.3% (Watson et al., 2003), in Latvia between 1995 and
2000, in the only tertiary level hospital 24.4% of sepsis
cases were fatal (Gardovska et al., 2001). The diagnosis of
sepsis remains difficult due to a variety of reasons: in chil-
dren early warning signs and symptoms often are non-spe-
cific; microbiological results seldom made become avail-
able within 48–72 h; and false-negative results are common.
The most important measures in reducing mortality from
sepsis are the early recognition and prompt initiation of
therapy (Brilli et al., 2005; Randolph et al., 2005; Mishra et
al., 2006). In 2002, in the First International Pediatric Sep-
sis Consensus Conference specific clinical definitions of
systemic inflammatory response syndrome (SIRS) and sep-
sis in children were defined (Randolph et al., 2005). To-
gether with early clinical sepsis recognition, laboratory tests
are of great value in rapid diagnosis. In the adult population,
the International Sepsis Definitions Conference (2001) pro-
posed the use of biochemical and immunological markers
rather than relying on clinical signs to identify the inflam-
matory response (Levy et al., 2003). For many years, hema-
tological tests (total leukocyte count, neutrophils, band form
counts) and C-reactive protein (CRP) have been used for re-
liable diagnosis of sepsis. However, there do not have the
specificity required to distinguish between viral and bacte-
rial infections, autoimmune diseases, cancer and trauma
(Ballou and Kushner, 1992). Later the calcitonin prohorm-
one, procalcitonin (PCT) was proposed as a specific marker
of sepsis in children and adults (Hatheril et al., 1999; Guven
et al., 2002; Casado-Flores et al., 2003).
Lipopolysaccharide-binding protein (LBP) is an acute phase
protein involved in the endotoxin-mediated immune re-
sponse (Meisner, 2005). Increased serum LBP levels have
been reported in children with sepsis (Berner et al., 2002;
Pavcnik-Arnol et al., 2004; Ubernauf et al., 2007).
Interleukin-6 (IL-6), a proinflammatory cytokine that stimu-
lates both B- and T-lymphocytes is involved in the induc-
tion of fever (Ng et al., 2003; Carcillo et al., 2006) and has
attracted attention as an early inflammatory marker, with
levels correlating well with the severity and prognosis of
sepsis (Dahmet et al., 2005; Ng et al., 2006).
From 1999, when the protein secreted by macrophages
stimulated with lipopolysaccharide was found and identified
as high-mobility group box-1 protein (HMGB1), interest in
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this proinflammatory cytokine was noticeably increased
(Sunden-Cullberg et al., 2006). HMGB1 has been reported
as a “late-onset” cytokine. Higher HMGB1 levels have been
reported in sepsis patients compared to the healthy controls
(Gaini et al., 2007), some studies have demonstrated in-
creased levels of HMGB1 in patients with infection and
sepsis, whereas other investigators found no significant dif-
ference between infected and non-infected patients (Wang
et al., 1999; Hatada et al., 2005; Gaini et al., 2007a; Gaini
et al., 2007b).
The currently available evidence indicates that none of
markers to date meet the requirements for early and reliable
diagnosis of sepsis. Some results show that measurements
of combinations of biochemical markers may offer better
prospects for early diagnosis.
In children (particularly in all children age groups), com-
paratively fewer studies on early sepsis diagnosis and in-
flammatory markers (LBP, HMGB1) have been made.
The main aim was to investigate the levels of HMGB-1,
LBP, IL6, PCT and CRP in children with sepsis and SIRS
and to examine the ability of these markers to differentiate
sepsis from non-sepsis patients.
MATERIALS AND METHODS
Patients. Children with SIRS (n = 84) treated in the Chil-
dren’s Clinical University Hospital between January 2008
and January 2009 were included in this prospective study.
The group of patients enrolled in study was determined by
previous screening of children with changes in body tem-
perature (fever or hypothermia). SIRS criteria were as-
sessed, taking into account the values of vital signs appro-
priate to the child's age group, including body temperature,
heart rate, respiratory rate and leukocyte count (Goldstein et
al., 2005). Classification of the status of SIRS was done by
two clinicians blind of all the laboratory results.
Inclusion criteria were:
1. Presence of at least two of the following four criteria, of
which one must be temperature or leukocyte count
changes:
 Temperature > 38.5 or < 36 °C;
 Tachycardia (at least 2 SD above normal age group
value) or bradycardia in children < 1 year old (at least 2
SD below normal age group value);
 Respiratory rate > 2SD above normal age group value;
 Elevated or reduced leukocyte count according to nor-
mal age group values, or > 10% immature neutrophils.
2. Child’s age between seven days and 18 years.
3. Consent of parents for child’s participation in the study.
The enrolled children were divided into six age groups ac-
cording to the definitions of the International Sepsis Con-
sensus Conference.
Exclusion criteria
 Antibacterial therapy within the last 48 h
 Immunodeficiency
 Chronic/terminal liver or kidney illness
 Vaccination within five days before the start of the ill-
ness
 Any chronic illness that alters CRP levels
 Congenital metabolic defects
 Chromosomal anomalies
 Consent of parents not obtained.
A venous blood sample at time 0 and at the 24th and 48th
hours of the study was drawn. All analyses were made im-
mediately, excepted HMGB, for which the samples were
processed at frozen at –80 °C within 30 min of sampling.
Clinical and demographic data of the patients, systemic in-
flammatory response syndrome criteria, biochemical mark-
ers of inflammation (HMGB1, LBP, IL-6, PCT, CRP), and
total leukocyte count were analysed.
Sepsis was defined as systemic inflammatory response syn-
drome (SIRS) in the presence, or as a result, of suspected or
proven infection. The infection was defined as proven (by
positive culture, tissue strain), but evidence of infection in-
cluded positive clinical findings, imaging or laboratory tests
(white blood cells in sterile body fluid, pneumonia in radio-
graphic imaging, petechial or purpuric rash).
The study protocol had been approved by the Central Medi-
cal Ethics Committee of Latvia.
Laboratory assays. HMGB1 levels were measured with a
commercially available enzyme-linked immunosorbent as-
say (HMGB1 ELISA kit; Shino-Test Corporation, Tokyo,
Japan). The measuring range was 1 to 80 ng/ml, the coeffi-
cient of variation being < 10%. Recovery of HMGB1 in this
ELISA was 80–120%.
IL6 and LBP were by chemiluminescent immunometric as-
say Immulite® 2000 (Siemens Medical, Germany). The an-
alytical sensivity for IL6 was 2 pg/ml and 0.2 g/ml for
LBP.
The BRAHMS PCT-Q immunochromatografic test
(Brahms-Diagnostica, Germany) for the semi-quantitative
detection of PCT was used. PCT concentration ranges < 0.5,
 0.5,  2 and  10 ng/ml were detected with the help of a
reference card.
CRP levels were measured by the latex method (COBAS
INTEGRA; Roche professional Diagnostics), the lowest as-
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say sensitivity being 0.085 mg/L. CRP levels < 20 vmg/L
were accepted as normal.
White blood cells and neutrophils were counted on Advia
2120 (Siemens Medical, Germany).
All the laboratory analyses were carried out at the Children
Clinical University Hospital, only HMGB 1 was analysed in
the laboratory of Clinical Immunology and Immunogenet-
ics, Rîga Stradiòð University.
Statistical analyses. Results were presented as numbers (n),
percent (%), means ± standard deviation, and as medians
and interquartile ranges (IQR). Comparisons of measured
variables between SIRS and sepsis groups were performed
using the Mann-Whitney 2-independent sample test. A two-
tailed P value < 0.05 was considered statistically signifi-
cant. Receiver operator characteristic (ROC) curves and
area under the curve (AUC) were calculated for examined
markers. A two-tailed P value was calculated for AUC.
Sensitivities and specificities were calculated from cross-
tabulations. To detect significant correlations, the Spear-
man’s rank correlation test was used. All statistical calcula-
tions were performed using the SPSS and Epi Info 2000 sta-
tistical packages.
RESULTS
SIRS diagnosis and patients characteristics. In the pro-
spective study 84 SIRS patients were enrolled, in 23% (n =
19) of them sepsis was recognised. Patients were divided
into two groups — patients with SIRS without sepsis (n =
65) and patients with sepsis (n = 19). SIRS was most often
diagnosed by the fever in combination with tachycardia at
least 2 SD above normal age values, observed in 61% (n =
51) of all patients. Fever in combination with a respiratory
rate increased by > 2SD above normal age was noted in
53% (n = 45) of the cases. Fever associated with changes in
leukocyte count elevated or depressed for age was in 42%
(n = 35) of patients. Hypothermia was not detected. Similar
criteria combinations confirmed the SIRS diagnosis in both
the SIRS and sepsis patients groups; there was no statisti-
cally significant difference between them.
The clinical and demographical data of patients are pre-
sented in Table 1.
Levels of CRP, PCT, IL6, LBP and HMGB1 for SIRS
and sepsis patients. HMGB1 levels in the sepsis patient
group did not significantly differ from the SIRS patient
group. LBP levels were significantly higher among sepsis
group children compared those without sepsis (P < 0.05). IL
6 levels were significantly higher among sepsis group pa-
tients compared with patients with SIRS without sepsis (P <
0.05). CRP levels were significantly higher among the sep-
sis group compared with the SIRS group (P < 0.05) (Table
2). The PCT concentration was significantly higher in the
sepsis patients; a highest concentration above 10 ng/ml was
detected in significantly more cases in the sepsis group
(32%, n = 6) than in the SIRS group (3%, n = 2), and the
lowest PCT concentration was detected in significantly
more inpatients in the SIRS group (62%, n = 40) compared
with those in the sepsis patient group (16%, n = 3) (P <
0.01).
T a b l e 1
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Data are presented as the absolute number (%) or the median ± standard
deviation, standard error, with 95% confidence interval. SIRS, systemic in-
flammatory response syndrome; NS, not significant.
T a b l e 2











































Mann-Whitney test. Data presented as median and interquartile range
(IQR). 1P < 0.01. 2Compared with the previous group. SIRS, systemic in-
flammatory response syndrome. HMGB1, high mobility box-1 protein;
LBP, lipopolysaccharide-binding proteine; IL-6, interleukine-6; CRP,
C-reactive protein. NS, not significant.
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Correlations between markers. No correlations were
found between HMGB1 and any of the other biomarkers.
LBP correlated moderately well with IL6 (r = 0.662, P <
0.001) and CRP(r = 0.695, P < 0.001). A moderate correla-
tion was found between IL6 and LBP (r = 0.662, P < 0.001)
and CRP (r = 0.538, P < 0.001; Table 3).
Diagnostic abilities of HMGB1, LBP, IL6 and CRP in
diagnosing sepsis patients. To determine sepsis patients
from SIRS patients population in ROC analysis, LBP, IL6
and CRP had quite similar AUC values. IL-6 had the high-
est AUC of 0.79 (P < 0.001), CRP had an AUC of 0.78 (P <
0.001), and LBP an AUC of 0.73 (P < 0.001) (Fig. 1). The
diagnostic cut-off level with the optimal sensitivity and
specificity of LBP, IL-6 and CRP are shown in Table 4.
Abilities of HMGB1, LBP, IL6 and CRP in monitoring
of the disease process of sepsis patients. The median IL-6
and LBP levels decreased significantly (P < 0.001) in sepsis
patients group on the second day of the study (Table 5).
DISCUSSION
Only a comparatively narrow range of reports have been de-
voted to SIRS and sepsis in children. Our data broadly cor-
respond to other studies about sepsis development in SIRS
patients: 23% (n = 19) of the children we examined with
SIRS developed sepsis, accordingly 26% of adults with
SIRS developed sepsis in the study by Rangel–Fausto et al.
(1995), and 23% of children in the Proulx study (Proulx et
al., 1996). In our patients, SIRS diagnosis was confirmed
by combination of fever with tachycardia > 2 SD above the
age-normal values in 61% (n = 51) of cases, and this was
also observed in 85% of the children in the Carvalho study
(Carvalho et al., 2005). Fever and breathing rate of > 2 SD
above the age-normal value was noted in 53% (n = 45) of
cases in our study compared to 48% in the literature
(Carvalho et al., 2005). The mean age of SIRS patients in
our study was 71.3 months, but that of sepsis patients was
94.7 months, whereas the age most frequently mentioned in
the literature is 24 months (Carvalho et al., 2005), the possi-
ble difference arose because we did not have a neonatal pa-
tient group — our hospital does not have a maternity ward.
In recent years, HMGB1 has been very intensively investi-
gated as a proinflammatory cytokin. In 1999, Wang et al.
(1999) found increased levels of HMGB1 in 25 critically ill
patients with sepsis. Gaini et al. (2007b) maintained that
T a b l e 3
















































Fig. 1. Receiver operating characteristic curves (ROC) comparing LBP,
Il-6 and CRP prediction of sepsis. LBP, lipopolysaccharide-binding
proteine; IL-6, interleukine-6; CRP, C-reactive protein. P < 0.001.
T a b l e 4
OPTIMUM DIAGNOSTIC CUT-OFF VALUE, SENSITIVITY AND
SPECIFICITY OF LBP, IL-6 AND CRP IN DIAGNOSING SEPSIS IN
CHILDREN
Variable Cut-off level Sensitivity (%) Specificity (%)
CRP 80.4 mg/L 78.9 64.6
LBP 24.5 g/ml 78.9 50.8
IL6 44.5 pg/ml 78.9 70.8
LBP, lipopolysaccharide-binding protein; IL -6, interleukin-6; CRP,
C-reactive protein
T a b l e 5
LEVELS OF HMGB1, LBP, IL-6, CRP IN SEPSIS PATIENTS GROUPS
AT 0 AND 24th HOUR OF STUDY
Variable Hour of study Median IQR P value
CRP 0 137.8 80.8 – 218.4 0.099
24 125.7 54.1 – 217.5
IL-6 0 133.0 45.2 – 488.0 < 0.001
24 25.2 12.8 – 49.1
LBP 0 38.3 24.6 – 81.2 0.001
24 32.0 16.9 – 43.5
HMGB1 0 2.9 1.3 – 5.7 0.836
24 3.5 1.5 – 4.0
Wilcoxon test. Data presented as median and interquartile range (IQR).
IQR, Interquartile ranges; P < 0.01. HMGB1, high mobility box-1 protein;
LBP, lipopolysaccharide-binding proteine; IL -6, interleukine-6; CRP,
C-reactive protein. NS, not significant.
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HMGB1 levels failed to discriminate between patients with
infection and those without infection, but HMGB1 levels
were significantly higher in patients compared with healthy
controls. Similar findings were reported by Sunden-
Cullberg et al. (2005). Angus et al. (2007) found that
HMGB1 levels did not differ between those with and with-
out sepsis. One possible explanation for these divergent re-
sults could be the different laboratory methods used (West-
ern blot and ELISA). Using ELISA techniques markedly
lower HMGB1 levels were found. In our study using an
ELISA technique, median HMGB1 levels were 3.5 ng/ml
for sepsis patients, which are similar to the lower HMGB1
levels observed in others studies where ELISA technique
was used — Hatada et al. (2005) observed median HMGB1
levels of 4.5 ng/ml in infected patients, Yasuda et al. (2006)
measured HMGB1 levels of 7.7ng/ml in infected patients
with severe pancreatitis. Gaini et al. (2007a) in one of their
studies noted median HMGB1 levels of 2.2 ng/ml in sepsis
patients, and median levels of 4.3 ng/ml in sepsis patients in
their another study (Gaini et al., 2007b). Our median
HMGB1 levels did not differ significantly between the
group of SIRS patients and of sepsis patients. We found no
correlation between levels of HMGB1 and levels of the
other investigated markers and, for this reason ROC analy-
sis was not conducted for HMGB1 in the diagnosis of sepsis
patients. We have several explanations for the above results:
our patient population consisted of children, and to date no
other study has been conducted in a population of children;
patients were less ill compared with patients from intensive
care units; HMGB1 is the “late-onset” cytokine and patients
in our study were included in comparatively early stage of
disease. HMGB1 was not a good indicator in identifying
and monitoring sepsis patients. Future studies need to
broaden the children population under investigation and to
test for their correlation of HMGB1 levels with the disease
process.
Elevated LBP levels have been seen in infections caused by
Gram positive and negative bacteria both in adult (Blairon
et al., 2003; Froon et al., 1994) and children populations
(Ubenauf et al., 2007). We found a moderate correlation be-
tween LBP and CRP, which concurs with the findings of
Gaini et al. (2007a) and partly with their findings in their
other publication where a strong correlation was found
(Gaini et al., 2006). We saw a moderate correlation between
LBP and IL6, which was also found by Gaini and collegues
(Gaini et al., 2006). Our LBP levels were significantly
higher in sepsis patients — median 38.3 g/ml compared
with median LBP level 25.2 g/ml in the SIRS group pa-
tients. Gaini et al. (2006) quoted a median LBP level of
33.5 g/ml for sepsis patients and 40.4 g/ml for severe
sepsis patients. Our results for LBP levels in sepsis patients
corresponded with the results of a study on children with in-
vasive bacterial infections — median LBP levels of 45.0
g/ml LBP for this group (Gaini et al., 2007a). Pavcnik-
Arnol et al. (2004) found lower LBP concentrations in SIRS
patients with sepsis from population of critically ill neo-
nates (27.1 g/ml) and in children with SIRS without sepsis
(10.5 g/ml). Our results on the LBP ability to diagnose
sepsis partly substantiates this sensitivity 79.9% and speci-
ficity 50.8%, with a cut-off level of 24.5 g/ml. In other
studies, a cut-off level of 20 g/ml LBP was associated with
91% sensitivity and 85% specificity (Pavcnik-Arnol et al.,
2004); 81% sensitivity and 68.4% (Gaini at al., 2006). LBP
did not perform perfectly on ROC analysis in its ability to
identify sepsis patients, with an AUC of 0.73 which differs
from that reported in a study by Pavcnik-Arnol et al.
(2007): AUC for LBP was 0.97 in neonates aged under 48
h, 0.93 in neonates over 48 h and 0.82 in older children. Our
results differ possibly because of the differences in the age
groups explored — older children were studied in our hos-
pital which explains why our AUC results were closer to
those reported by Pavcnik-Arnol et al. (2007) in children
not in the neonatal age group. Also, our study did not cover
critically ill patients as in other studies.
The levels of the inflammatory cytokine IL6 at the outset
were markedly higher in sepsis patients than in SIRS pa-
tients. These results match those of other studies on the role
of IL6 in differentiation of SIRS from sepsis patients in in-
tensive care units, facial–maxillary surgery, general surgery
and neonatal age patients (Mokart et al., 2005; Miyoka et
al., 2005; Silveira et al., 1999; Oda et al., 2005; Pan et al.,
2003; Riche et al., 2000). The median IL6 level for sepsis
patients in our study is similar to the median IL6 levels
from Gaini et al. (2006) as is the median IL6 for patients
with SIRS without sepsis (21 pg/ml and 20 pg/ml, respec-
tively). We found a moderate correlation between IL 6 and
LBP which is consistent with findings from the study by
Gaini et al. (2006). We obtained a cut-off level of 44.5
pg/ml for IL-6, which is relatively close to the results by
Silveira et al. (1999), who recorded a cut-off of 32 pg/ml
for neonatal sepsis diagnosis. In ROC analysis, IL-6 per-
formed the best from our markers, with an AUC 0.79 which
is close to results of Groselj-Grenc et al. (2007) — AUC
0.776 for acute appendicitis diagnosis in children, and mar-
ginally different from AUC results in Pavcnik-Arnol et al.
(2004) study — 0.67 (mainly the neonatal age group was
studied), and their results from the adult population — AUC
0.65 (Gaini et al., 2006).
IL-6 and LPB levels increased significantly in sepsis pa-
tients on the second day of study, confirming that IL-6 and
LBP are early inflammatory markers, the levels of which
decreases sharply if appropriate therapy is initiated (Pan et
al., 2003).
In our study, 39% (n = 25) of the SIRS patients and 84% (n
= 16) in the sepsis group had elevated PCT levels. Several
studies suggest that PCT provides less diagnostic accuracy
than previously supposed (Pavcnik-Arnol et al., 2004;
Thayyil et al., 2005; Gaini et al., 2006). Our results match
the literature data in respect to the correlation between PCT
level and the intensity of inflammation. The extent to which
the PCT concentration is elevated could possibly be a useful
laboratory tool for recognising sepsis patients, because 48%
(n = 9) of the sepsis patients, even at the beginning of the
illness, had concentrations > 2 ng/ml compared with the
SIRS group in which only 14% (n = 9) had a concentration
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> 2 ng/ml. These results correspond with those of Hatherill
et al. (1999) and Rey et al. (2007) (patients with localised
bacterial infections and sepsis had PCT > 2 ng/ml) and with
the data of Guven et al. (2002) (significantly elevated
changes in PCT in the early stages of disease were indica-
tive of a greater probability that sepsis would develop). In
conclusion, the method chosen for PCT detection in our
study (for financial reasons) did not fulfill our expectations,
the data were difficult to analyse statistically compared with
similar data from other studies.
The statistically significant differences in CRP that we ob-
served between SIRS and sepsis patients were also found in
other studies (Gaini et al., 2006; Kocabas et al., 2007).
During the study for all patients two separate blood cultures
were performed, the pathogen was recognised in the blood
of only 16% (n = 3) of sepsis patients. We did not further
analyse these data.
The strength of our study is the possibility of examining a
children population where to date only few studies are done.
The study focussed on early sepsis diagnosis in children
population using inflammatory markers that have been in-
tensively investigated during recent years. The patients in-
cluded in our study represented the average population ad-
mitted to the Children’s Hospital which was in accordance
with the aim of our study: to obtain the research results that
may be useful in future clinical practice for early sepsis di-
agnosis by using effective diagnostic markers.
Summarising the above discussion, we can conclude that in
early sepsis diagnosis in children, LBP, IL-6, PCT and CRP
are probably the superior diagnostic markers, with the best
performance by IL6. LBP and IL-6 are the superior markers
for monitoring of sepsis patients in dynamics and could be
used as indicators for evaluation of initiated empiric ther-
apy. The role of HMGB as an inflammatory cytokine in
children has not been thoroughly explored. Our results sug-
gest that HMGB1 does not have a diagnostic value in differ-
entiating sepsis patients from those in the SIRS group. In
view of the relatively small number of subjects in the sepsis
group, current evidence only allows us to suggest that par-
ticular attention should be paid to SIRS patients with ele-
vated levels of the above-mentioned inflammatory indica-
tors. There is a need to find new, specific and sensitive
inflammatory markers, as well as combinations of markers,
in SIRS patients that will enable sepsis to be diagnosed
early.
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DIAGNOSTISKIE MARÍIERI AGRÎNAI SEPSES NOTEIKÐANAI BÇRNIEM AR SISTÇMISKÂ IEKAISUMA ATBILDES
SINDROMU
Infekcijas izraisîta sepses joprojâm ir viens no vadoðiem mirstîbas cçloòiem bçrniem. Liela nozîme sepses mirstîbas mazinâðanâ ir prasmei
to savlaicîgi atpazît un agrîni uzsâkt terapiju. Jaunâkie pçtîjumu rezultâti liecina, ka tieði sensitîviem un specifiskiem bioíîmiskiem
maríieriem ir aizvien pieaugoða loma agrînâ sepses diagnostikâ. Pçtîjuma mçríis – izpçtît high–mobility group box-1 protein (HMGB1),
lipopolisaharîdus saistoðâ olbaltuma (LBP), interleikîna 6 (IL-6), prokalcitonîna (PCT), C reaktîvâ proteîna (CRP) noteikðanas lietderîgumu
agrînai sepses diagnostikai bçrniem ar sistçmiskâ iekaisuma atbildes sindromu (SIRS). Prospektîvâ pçtîjumâ tika iekïauti 84 bçrni ar
sistçmiskâ iekaisuma atbildes sindromu (SIRS). Sepse tika konstatçta 23% (n = 19) pçtîjuma pacientu. LBP, IL-6, CRP un PCT lîmeòi
statistiski ticami bija augstâki sepses pacientu grupâ (P < 0.05). HMGB1 lîmenis abâm pacientu grupâm nebija statistiski ticami atðíirîgs.
Sepses pacientu ROC analîþu rezultâti iekaisuma maríieriem LBP, IL6 un CRP bija pietuvinâti(P < 0.001), tomçr IL6 uzrâdîja labâko
rezultâtu. Mûsu rezultâti norâda, ka iekaisuma indikatorus LBP, IL-6, PCT un CRP var izmantot agrînai sepses pacientu identificçðanai, IL6
uzskatâms par precîzâko no ðiem maríieriem. Sepses pacientu slimîbas procesa monitorçðanai precîzâki ir LBP un IL-6. Iekaisuma
maríierim HMGB1 netika konstatçta diagnostiska nozîme sepses pacientu identificçðanas procesâ.
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